A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS

The KRAS gain-of-function mutation confers intrinsic resistance to targeted anti-cancer drugs and cytotoxic chemotherapeutic agents, ultimately leading to treatment failure. KRAS mutation frequency in lung adenocarcinoma is ~15–30%. Novel therapeutic strategies should be developed to improve clinical outcomes in these cases. Deregulation of the p16/cyclin-dependent kinase (CDK) 4/retinoblastoma (Rb) pathway is frequently observed in various cancers and it represents an attractive therapeutic target. We compared the anti-tumor efficacy of genetically knocked-down CDK4 and a pharmacological inhibitor of CDK4/6, CINK4, in KRAS mutation-positive lung adenocarcinoma cells. We also investigated changes in anti-proliferative activity and downstream molecules with these treatments in combination with paclitaxel. CDK4 short interfering RNA (siRNA) significantly increased paclitaxel sensitivity in KRAS mutation-positive H23 cells. CINK4 demonstrated concentration- and time-dependent anti-proliferative activity in 5 adenocarcinoma lines. CINK4 induced G1 arrest by downregulating the p16/cyclin D1/Rb pathway, resulting in apoptotic induction via increased expression of cleaved caspase3, cleaved PARP and Bax. Combined CINK4 and paclitaxel produced synergistic anti-proliferative activity and increased apoptosis through reduced cyclin D1 and Bcl-2 in KRAS mutation-positive cancer cells. These data suggest CDK4 is a promising target for development of anti-cancer drugs and CINK4 combined with paclitaxel may be an effective therapeutic strategy for enhancing anti-tumor efficacy in KRAS mutation-positive lung adenocarcinoma.

• Publication year

  2013

• Venue

  Cancer Biology & Therapy

• Publication date

  2013-05-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cbt.24592PMID 23792647PMCID 3742489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.

  2012cited by this paper
• MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

  2012cited by this paper
• Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

  2011cited by this paper
• Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides.

  2011cited by this paper
• Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

  2011cited by this paper
• Promising human brain tumors therapy with interference RNA intervention (iRNAi)

  2010cited by this paper
• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  2010cited by this paper
• Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.

  2010cited by this paper
• Cell-cycle control in the face of damage--a matter of life or death.

  2009cited by this paper
• Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes.

  2009cited by this paper
• KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

  2008cited by this paper
• Transcriptional regulation of the cyclin D1 gene at a glance

  2008cited by this paper
• Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

  2008cited by this paper
• Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer

  2008cited by this paper
• ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

  2007cited by this paper
• p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells.

  2007cited by this paper
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

  2007cited by this paper
• KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

  2007cited by this paper
• Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression.

  2006cited by this paper
• Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6.

  2004cited by this paper
• Cell-cycle checkpoints and cancer

  2004cited by this paper
• Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

  2004cited by this paper
• The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

  2004cited by this paper
• Microarray Analyses Uncover UBE1L as a Candidate Target Gene for Lung Cancer Chemoprevention

  2004cited by this paper
• Signal transduction pathways of taxanes-induced apoptosis.

  2003cited by this paper
• Cyclin D1 as a target for chemoprevention.

  2003cited by this paper
• Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells

  2002cited by this paper
• CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis

  2002cited by this paper
• Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity

  2001cited by this paper
• Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

  2001cited by this paper
• Challenges of cancer drug design: a drug metabolism perspective.

  2001cited by this paper
• Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

  2000cited by this paper
• Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas.

  1999cited by this paper
• Association of K-ras mutations with p16 methylation in human colon cancer.

  1999cited by this paper
• Association of CDKN2A (p16)/CDKN2B (p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma

  1998cited by this paper
• Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).

  1998cited by this paper
• Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth.

  1997cited by this paper
• Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth.

  1997cited by this paper
• Cyclin D 1 antisense RNA destabilizes pRb and retards lung cancer cell growth

  1997cited by this paper
• Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase.

  1997cited by this paper
• Detection of K-ras mutations in lung carcinomas: relationship to prognosis.

  1996cited by this paper
• Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.

  1995cited by this paper
• Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.

  1995cited by this paper
• Inhibition of ras-induced proliferation and cellular transformation by p16INK4

  1995cited by this paper
• Identification of G1 kinase activity for cdk6, a novel cyclin D partner

  1994cited by this paper
• D-type cyclin-dependent kinase activity in mammalian cells

  1994cited by this paper
• Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

  1993cited by this paper
• A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

  1993cited by this paper
• Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.

  1993cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.

  1988cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)

  2025cites this paper
• Mechanisms of Action and Indications of Cyclin‐Dependent Kinase Inhibitors with Benzoheterocycle Scaffolds

  2025cites this paper
• Abemaciclib induces G1 arrest and lysosomal dysfunction in canine melanoma cells: synergistic effects with fenbendazole

  2025cites this paper
• An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations

  2025cites this paper
• Deletion of the Long Non-coding RNA ANRIL In Addition to the Protein-Coding Genes of the INK4-ARF Locus in the A549 Cell Line: An Existing Phenomenon or a Novel Genetic Alteration?

  2025cites this paper
• Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance.

  2024cites this paper
• Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges

  2022cites this paper
• Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel

  2022cites this paper
• A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer.

  2022cites this paper
• Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations

  2021cites this paper
• Cyclin-dependent kinase inhibitors for the treatment of lung cancer

  2020cites this paper
• Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

  2020cites this paper
• GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence

  2020cites this paper
• SPH3643: A novel cyclin‐dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood‐brain barrier permeability

  2020cites this paper
• P16 Methylation Leads to Paclitaxel Resistance of Advanced Non-Small Cell Lung Cancer

  2019cites this paper
• Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer

  2019cites this paper
• Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity

  2019cites this paper
• Drug Combinatorial Therapies for Treatment of KRAS Mutated Lung Cancers.

  2019cites this paper
• Mutation Testing of Lung Cancer Biomarkers (Excluding IHC and NGS)

  2018cites this paper
• Lower miR-340 expression predicts poor prognosis of non-small cell lung cancer and promotes cell proliferation by targeting CDK4.

  2018cites this paper
• Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

  2018cites this paper
• Circulating DNA for the in vivo detection and monitoring of lung cancer

  2018cites this paper
• Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss

  2017cites this paper
• A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level

  2017cites this paper
• Molecular genetics and cellular events of K-Ras-driven tumorigenesis

  2017cites this paper
• CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

  2017cites this paper
• Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo

  2016cites this paper
• Dual-targeting of MEK and CDK4/6 in KRAS-mutated Non-Small Cell Lung Cancer

  2016cites this paper
• Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer

  2016cites this paper
• Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy

  2016cites this paper
• Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel

  2016cites this paper
• Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

  2015cites this paper
• Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

  2015cites this paper
• Therapeutic targeting of replicative immortality

  2015cites this paper
• Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance.

  2014cites this paper
• Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.

  2014cites this paper
• Targets of MiRNAs in lung cancer related pathways as predictors of chronic obstructive pulmonary disease

  2014cites this paper
• Potencial estrogênico, antimutagênico e antigenotóxico de extratos e substâncias isoladas do gênero Syngonanthus (Eriocaulaceae) e efeito inibidor na expressão de genes por xantonas de Syngonanthus nitens

  2013cites this paper